Summit Therapeutics Targets $3.73B Cap in Oncology Drive
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’ ratings from Citigroup and Stifel, and robust institutional support. Summit Therapeutics Inc. (NASDAQ: SMMT) is a …
Summit Therapeutics Targets $3.73B Cap in Oncology Drive Read More »